TATVA

Tatva Chintan Pharma Chem Share Price Tatva Chintan Pharma Chem

₹1,166.2
-26.55 (-2.23%)
09 May, 2024 17:33 BSE: 543321 NSE: TATVAISIN: INE0GK401011

Start SIP in Tatva Chintan Pharma Chem

Start SIP

Tatva Chintan Pharma Chem Performance

Day Range

  • Low 1,160
  • High 1,211
₹ 1,166

52 Week Range

  • Low 1,061
  • High 1,888
₹ 1,166
  • Open Price1,211
  • Previous Close1,193
  • Volume9953

Tatva Chintan Pharma Chem Share Price

  • Over 1 Month -8.44%
  • Over 3 Month -9.8%
  • Over 6 Month -22.82%
  • Over 1 Year -30.61%

Tatva Chintan Pharma Chem Key Statistics

P/E Ratio 89.9
PEG Ratio -2.7
Market Cap Cr 2,728
Price to Book Ratio 3.7
EPS 12.5
Dividend 0.2
Relative Strength Index 42.03
Money Flow Index 26.93
MACD Signal 3.47
Average True Range 36.82
Tatva Chintan Pharma Chem Financials
IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 948693106119
Operating Expenses Qtr Cr 80747286104
Operating Profit Qtr Cr 1412212015
Depreciation Qtr Cr 67763
Interest Qtr Cr 00333
Tax Qtr Cr 4243-9
Net Profit Qtr Cr 858816
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 386409
Operating Expenses Annual Cr 312348
Operating Profit Annual in Cr 6755
Depreciation Cr 2610
Interest Annual Cr 78
Tax Annual Cr 13-2
Net Profit Annual Cr 2940
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 10324
Cash from Investing Activity Annual Cr -121-101
Cash from Financing Annual Activity Cr 3138
Net Cash Flow Annual Cr -40
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 726505
Fixed Assets Annual Cr 503427
Total Non Current Assets Annual Cr 521443
Total Current Assets Annual Cr 294311
Total Assets Annual Cr 815755
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 310228
ROE Annual % 48
ROCE Annual % 710
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2015
IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 988497114125
Operating Expenses Qtr Cr 83737693108
Operating Profit Qtr Cr 1611202116
Depreciation Qtr Cr 67763
Interest Qtr Cr 00333
Tax Qtr Cr 4234-9
Net Profit Qtr Cr 10381017
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 401429
Operating Expenses Annual Cr 325363
Operating Profit Annual in Cr 6861
Depreciation Cr 2610
Interest Annual Cr 78
Tax Annual Cr 13-1
Net Profit Annual Cr 3045
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 9828
Cash from Investing Activity Annual Cr -121-101
Cash from Financing Annual Activity Cr 3138
Net Cash Flow Annual Cr -36
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 737515
Fixed Assets Annual Cr 503427
Total Non Current Assets Annual Cr 521443
Total Current Assets Annual Cr 298314
Total Assets Annual Cr 819756
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 315232
ROE Annual % 49
ROCE Annual % 711
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1916

Tatva Chintan Pharma Chem Technicals

EMA & SMA

Current Price
₹1,166.2
-26.55 (-2.23%)
pointer
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 16
  • 20 Day
  • ₹1,222.58
  • 50 Day
  • ₹1,241.09
  • 100 Day
  • ₹1,310.61
  • 200 Day
  • ₹1,446.23
  • 20 Day
  • ₹1,237.17
  • 50 Day
  • ₹1,211.51
  • 100 Day
  • ₹1,329.59
  • 200 Day
  • ₹1,463.30

Tatva Chintan Pharma Chem Resistance and Support

PIVOT
₹1,195.12
Resistance
First Resistance 1,200.23
Second Resistance 1,207.72
Third Resistance 1,212.83
RSI 42.03
MFI 26.93
MACD Single Line 3.47
MACD -1.79
Support
First Resistance 1,187.63
Second Resistance 1,182.52
Third Resistance 1,175.03

Tatva Chintan Pharma Chem Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 11,362 786,478 69.22
Week 17,375 907,486 52.23
1 Month 16,400 781,301 47.64
6 Month 31,769 1,780,044 56.03

Tatva Chintan Pharma Chem Result Highlights

Tatva Chintan Pharma Chem Synopsis

NSE-Chemicals-Basic

Tatva Chintan Pharm is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company’s Total Operating Revenue is Rs. 403.04 Cr. and Equity Capital is Rs. 22.17 Cr. for the Year ended 31/03/2023. Tatva Chintan Pharma Chem Ltd. is a Public Limited Listed company incorporated on 12/06/1996 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ1996PLC029894 and registration number is 029894.
Market Cap 2,733
Sales 379
Shares in Float 0.65
No of funds 35
Yield 0.16
Book Value 3.84
U/D Vol ratio 0.9
LTDebt / Equity 1
Alpha -0.17
Beta 0.51

Tatva Chintan Pharma Chem

Owner NameMar-24Dec-23Sep-23Aug-23
Promoters 72.02%72.02%72.02%75.02%
Mutual Funds 12.84%13.05%13.54%13.57%
Insurance Companies 0.11%0.11%
Foreign Portfolio Investors 3.65%4.21%4.4%4.13%
Individual Investors 10.49%9.39%8.72%6.23%
Others 1%1.33%1.21%0.94%

Tatva Chintan Pharma Chem Management

Name Designation
Mr. Chintan Nitinkumar Shah Chairman & Managing Director
Mr. Ajaykumar Mansukhlal Patel Whole Time Director
Mr. Shekhar Rasiklal Somani Whole Time Director
Dr. Manher Chimanlal Desai Independent Director
Mr. Subhash Ambubhai Patel Independent Director
Dr. Avani Rajesh Umatt Independent Director

Tatva Chintan Pharma Chem Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Tatva Chintan Pharma Chem Corporate Action

Date Purpose Remarks
2024-05-03 Audited Results & Final Dividend
2024-01-20 Quarterly Results
2023-11-02 Quarterly Results
2023-08-04 Quarterly Results
2023-07-11 Preferential issue of shares
Date Purpose Remarks
2022-09-09 FINAL Rs.2.00 per share(20%)Final Dividend

Tatva Chintan Pharma Chem FAQs

What is Share Price of Tatva Chintan Pharma Chem ?

Tatva Chintan Pharma Chem share price is ₹1,166 As on 09 May, 2024 | 17:19

What is the Market Cap of Tatva Chintan Pharma Chem ?

The Market Cap of Tatva Chintan Pharma Chem is ₹2728 Cr As on 09 May, 2024 | 17:19

What is the P/E ratio of Tatva Chintan Pharma Chem ?

The P/E ratio of Tatva Chintan Pharma Chem is 89.9 As on 09 May, 2024 | 17:19

What is the PB ratio of Tatva Chintan Pharma Chem ?

The PB ratio of Tatva Chintan Pharma Chem is 3.7 As on 09 May, 2024 | 17:19

Q2FY23